Future obesity drugs must provide improved efficacy and safety, says GBI Research
A highly innovative and diverse pipeline of 248 products in active development is set to tackle the ever-encroaching obesity crisis.
Analysis from business intelligence provider GBI Research — Frontier Pharma: Obesity — Identifying and Commercializing First-in-Class Innovation — states that despite the current market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class.
While most pipeline products target gut hormone receptors, the remainder target a wide range of processes thought to be dysregulated in obesity, such as angiogenesis, insulin signalling, inflammation, fat absorption, lipid synthesis, and metabolism.
Senior Analyst Angel Wong: "The high level of innovation and diversity in molecular target in development is encouraging, with a number of these not only showing close alignment to the disease pathophysiology but also addressing multiple mechanisms underpinning the development of obesity.
"As obesity is a multifactorial disease, targeting multiple systems may potentially avoid compensatory mechanisms that lead to weight regain and achieve sustainable weight loss over the long term."
The analyst also says that small molecules, accounting for 66% of the overall pipeline, are the dominant molecule type in all stages of development for obesity treatment. Biologic therapeutics, consisting largely of peptides, proteins, antibodies and vaccines, also feature prominently.
GBI Research's report also states that the long-term treatment options for obesity remain sparse, including the dietary fat absorption inhibitor Xenical (orlistat), and appetite suppressants including Qsymia (phentermine and topiramate extended release), Belviq (lorcaserin hydrochloride), and the two new market entrants Contrave (naltrexone and bupropion) and Saxenda (liraglutide rDNA origin).
Wong continues: "Prescription of these treatments is generally limited, primarily due to concerns over their long-term safety, with the past decade seeing a number of drug withdrawals in the market as a result of serious cardiovascular risks and psychiatric adverse reactions.
"The uptake of anti-obesity drugs has also been hindered by their modest efficacy in inducing sustained body weight reduction. All of these factors are driving efforts to address the significant unmet need for effective obesity therapeutics with favorable safety profiles," the analyst concludes.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance